Titan Pharmaceuticals Schedules Conference Call to Review First Quarter 2016 Financial Results May 4, 2016
Titan Pharmaceuticals Announces Presentation of Probuphine Phase 3 Data at American Society of Addiction Medicine Annual Conference April 15, 2016
Titan Pharmaceuticals Schedules Conference Call to Review Fourth Quarter and Full Year 2015 Financial Results March 8, 2016
Titan Pharmaceuticals Receives Feedback From FDA on Ropinirole Implant Development Program for Parkinson's Disease March 7, 2016
Titan Pharmaceuticals Announces Notification of FDA Action Date Extension for Probuphine February 19, 2016
Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce FDA Advisory Committee Recommends Approval of Probuphine, First 6-Month Implant to Treat Opioid Addiction January 12, 2016
Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce Date of FDA Advisory Committee Review of Probuphine for Opioid Addiction December 9, 2015
